OGG1 inhibitors against acute lung injury

Reference number 2018-03232
Coordinator Oxcia AB
Funding from Vinnova SEK 5 000 000
Project duration November 2018 - November 2020
Status Ongoing
Venture SWElife Phase 2 2017
Call 2018-02544-en

Purpose and goal

The goal with the project is to develop safe and effective OGG1 inhibitors for acute lung injury. Another goal is to develop a business strategy including a market analysis to enable the project to continue through preclinical phase (GLP-tox studies) and thereafter sell or outlicense the project.

Expected results and effects

Selected compound is expected to be safe and demonstrate significant anti-inflammatory effects. We also expect to have developed a business strategy for the proceeding after this project has been finalized.

Planned approach and implementation

Development of the compounds, and identification of promising potential candidate drug will be performed at Helleday lab at KI. Physical/biophysical and ADME characterization of the compounds will be performed at UDOPP, Uppsala U. Pharmacodynamic studies in models of acute lung injury will be performed att Lund U. Preliminary safety-studies will be outsourced to CRO, administered by Oxcia AB. Business-, IPR- and regulatory strategies will be developed and handed by Oxcia AB.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.